The cooperative complex of Argonaute-2 and microRNA-146a regulates hepatitis B virus replication through flap endonuclease 1

Ji, Min; Mei, Xiaoping; Jing, Xueming; Xu, Xu; Chen, Xing; Pan, Wanlong

doi:10.1016/j.lfs.2020.118089

Cited by 8 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AGO3 deletion signi cantly inhibits the growth and migration of cervical cancer cells, and AGO3 knockdown inhibits cell behavior by inactivating the Wnt/β-catenin signaling pathway [43]. AGO2 cooperates with miR-146a to regulate the transcription and expression levels of Flap endonuclease 1 through downstream target genes interleukin-1 receptor-associated kinase 1 (IRAK1) and tumor necrosis factor receptor-associated factor-6 (TRAF6), and promotes Hepatitis B virus replication [44]. Cricket paralysis virus encodes RNAi inhibitor 1A, which regulates viral virulence.…”

Section: Ago Protein Defense Mechanismmentioning

confidence: 99%

Research Advances in Argonaute Proteins

Wei

Zhang

Gao

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Argonaute (AGO) is a large family of proteins and a primary component of the RNA-induced silencing complex (RISC). AGO proteins play important roles in regulatory processes, including RNA interference (RNAi) and gene silencing involving many small RNAs. RISC recognizes RNA by base complementary pairing and cleaves or suppresses translation to silence related genes. AGO proteins contain two domains: P-element induced wimpy testis (PIWI) and PIWI-Argonaute-Zwille, which can interact with small interfering RNA or target mRNA and play a key role in RNAi. The AGO protein family is also involved in biological defense mechanisms and may even become a new genome editing tool. Methods and Results: This review collates and summarizes relevant literature in AGO protein research and describes the biological structure, functions, and characteristics of AGO proteins. Conclusions: This review paper will provide a reference for related research and applications.

show abstract

Section: Ago Protein Defense Mechanismmentioning

confidence: 99%

Research Advances in Argonaute Proteins

Wei

Zhang

Gao

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…They found that AGO2-miR-20a binding to the cccDNA may recruit DNMT3 to silence gene expression; however, further studies are needed to confirm the exact mechanism. Interestingly miR-146a could play a role in cccDNA formation, through a positive feedback loop with FEN1[ 176 ], and in silencing ZEB2 expression[ 177 ].…”

Section: Regulatory Noncoding Rnasmentioning

confidence: 99%

Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach

Singh

Kairuz

Arbuthnot

et al. 2021

WJG

View full text Add to dashboard Cite

Global prophylactic vaccination programmes have helped to curb new hepatitis B virus (HBV) infections. However, it is estimated that nearly 300 million people are chronically infected and have a high risk of developing hepatocellular carcinoma. As such, HBV remains a serious health priority and the development of novel curative therapeutics is urgently needed. Chronic HBV infection has been attributed to the persistence of the covalently closed circular DNA (cccDNA) which establishes itself as a minichromosome in the nucleus of hepatocytes. As the viral transcription intermediate, the cccDNA is responsible for producing new virions and perpetuating infection. HBV is dependent on various host factors for cccDNA formation and the minichromosome is amenable to epigenetic modifications. Two HBV proteins, X (HBx) and core (HBc) promote viral replication by modulating the cccDNA epigenome and regulating host cell responses. This includes viral and host gene expression, chromatin remodeling, DNA methylation, the antiviral immune response, apoptosis, and ubiquitination. Elimination of the cccDNA minichromosome would result in a sterilizing cure; however, this may be difficult to achieve. Epigenetic therapies could permanently silence the cccDNA minichromosome and promote a functional cure. This review explores the cccDNA epigenome, how host and viral factors influence transcription, and the recent epigenetic therapies and epigenome engineering approaches that have been described.

show abstract

“…Ideal carriers are responsible for high gene transfection efficiency, and their development has attracted considerable efforts. − Remarkably, effective therapeutic genes guarantee the expression of functional proteins, which is also the key to gene therapy . To break through the bottlenecks of gene therapy, we should pay more attention to the key points such as therapeutic genes besides gene carriers, for amplifying the expression of functional proteins. − …”

Section: Introductionmentioning

confidence: 99%

Unexpected Amplification of Synergistic Gene Expression to Boom Vascular Flow in Advantageous Dual-Gene Co-expression Plasmid Delivery Systems over Physically Mixed Strategy

Wang

Gao

Zhou

et al. 2020

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Gene therapy exerts powerful potential in the treatment of various diseases, such as overexpressing pro-angiogenic gene to accelerate angiogenesis and restore vascular flow of ischemic tissue. Tremendous efforts have been invested in developing gene carriers for high transfection efficiency, while little research has been devoted to synergistically expressing functional proteins via optimizing therapeutic genes. Actually, the amplified gene expression is the ultimate goal of gene delivery. Dual-gene co-delivery and coordinate expression become a “breach” of strengthened gene expression. Herein, we explored the synergistic effects on gene expression and pro-angiogenesis by two typical dual-gene delivery strategies to determine which one is more efficient. The physical mixing method used ZNF580 and VEGF165 plasmids with a 1/1 weight ratio (p1:1), and the other strategy involved chemically inserting ZNF580 and VEGF165 genes into one plasmid as a dual-gene co-expression plasmid (pZNF–VEGF). p1:1 and pZNF–VEGF were loaded by REDV–TAT–NLS–H12 carrier, a promising peptide carrier, to form corresponding dual-gene delivery systems. Both systems exhibited approximately similar size and zeta potential, guaranteeing almost the same cellular uptake. We comprehensively evaluated two delivery systems through gene expression at mRNA and protein levels and angiogenesis-related activities in vitro and in vivo. Interestingly, the pZNF–VEGF group showed a remarkably amplified synergistic effect in the expression of ZNF580 and VEGF165 genes in comparison with the p1:1 group. More importantly, the unexpected amplified synergistic effect of dual-gene co-expression plasmid was further verified for proliferation, migration, and angiogenesis in vitro and in vivo. Accordingly, we believed that the co-delivery of dual genes via constructing co-expression plasmids offers a better option for gene therapy, which can more effectively enhance the synergistic expression of target genes than the physical mixing method.

show abstract

The cooperative complex of Argonaute-2 and microRNA-146a regulates hepatitis B virus replication through flap endonuclease 1

Cited by 8 publications

References 21 publications

Research Advances in Argonaute Proteins

Research Advances in Argonaute Proteins

Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach

Unexpected Amplification of Synergistic Gene Expression to Boom Vascular Flow in Advantageous Dual-Gene Co-expression Plasmid Delivery Systems over Physically Mixed Strategy

Contact Info

Product

Resources

About